pharma webinar

What’s Next for U.S. Drug Pricing and Domestic Production

August 7, 2020

APCO hosted a discussion around the recent Trump Administration executive orders on drug pricing and the announcement of using the Defense Production Act to spur increased U.S.-based pharmaceutical ingredients manufacturing as the nation gears up to come back stronger. Panelists were APCO IAC member and policy expert Dr. Kavita Patel; PhRMA General Counsel and former HHS acting general counsel, Jim Stansel; former FDA Chief Counsel and Sidley partner Becky Wood. I had the privilege of serving as moderator.

The discussion covered a range of timely topics including the policy and political ramifications of the executive orders, how drug pricing actions will resonate considering the pandemic and which of these policies might move forward in 2021. We fully discussed the pharmaceutical industry’s strong reaction in opposing the most favored nation pricing proposal, its support of the effort to reform the system of providing rebates to “middlemen” and the challenges of drug importation. The discussion about the Kodak decision focused on the overall supply chain the challenges and opportunities.

Watch the full event here:

Related Articles

Riyadh, Saudi Arabia

Perspectives

How Saudi Arabia Became the Story

June 27, 2025
USIBC-APCO-SIA Space Tech Report

Perspectives

TRUST in Space: India-U.S. Collaboration Set to Grow the Global Space Economy Together

June 26, 2025
Container ship in ocean

Perspectives

Intermodality: Logistical Revolution in a Complex Geopolitical Context

June 25, 2025